Advertisement

Topics

HSBC hebt Ziel für Roche auf 205 Franken - 'Reduce'

03:07 EST 21 Nov 2017 | FinanzNachrichten

Die britische Investmentbank HSBC hat das Kursziel für Roche von 203 auf 205 Franken angehoben, die Einstufung aber auf "Reduce" belassen. Die Haven-3-Studie zu Hemlibra bei Patienten mit Hämophil...

Related Biotechnology, Pharmaceutical and Healthcare News

Original Article: HSBC hebt Ziel für Roche auf 205 Franken - 'Reduce'

NEXT ARTICLE

More From BioPortfolio on "HSBC hebt Ziel für Roche auf 205 Franken - 'Reduce'"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...


News Quicklinks

Search Biotech, Medical and Healthcare News

Popular Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches


BioPortfolio Limited Social Media
Publish Content Agreements
Tools Help

HON Code certificate This site complies with the HONcode standard for trustworthy health information:
Verify here.

The information provided by BioPortfolio.com is not a substitute for professional medical advice, diagnosis or treatment. The BioPortfolio site is sponsored BioPortfolio Limited with offices at Stafford House, 10 Prince of Wales Road, Dorchester, DT1 1PW, England. If you are a legal copyright holder or a designated agent for such and you believe a post on this website falls outside the boundaries of “Fair Use” and legitimately infringes on your or your client's copyright we may be contacted concerning copyright matters at: priority@bioportfolio.com.
All rights reserved. All other trademarks recognized. Copyright © 1997-2017 BioPortfolio Limited. Site developed by Alacrify Ltd.